Johns Hopkins HIV Guide
Dolutegravir
INDICATIONS
FDA
FDA
Tivicay: Treatment of HIV-1 infection in combination with other ARV agents in adults and children weighing ≥30 kg
Triumeq: Treatment of HIV-1 infection in adults and children weighing ≥40 kg
Juluca: Treatment of HIV-1 infection as a complete regimen for adult patients already virologically suppressed on stable ART for 6 months and no known resistance to dolutegravir or rilpivirine
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Non-occupational post-exposure prophylaxis (nPEP) in combination with other ARV agents
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 13, 2018
Citation
Smith, Janessa, and Paul A Pham. "Dolutegravir." Johns Hopkins HIV Guide, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545239/all/Dolutegravir.
Smith J, Pham PA. Dolutegravir. Johns Hopkins HIV Guide. 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545239/all/Dolutegravir. Accessed September 23, 2023.
Smith, J., & Pham, P. A. (2018). Dolutegravir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545239/all/Dolutegravir
Smith J, Pham PA. Dolutegravir [Internet]. In: Johns Hopkins HIV Guide. ; 2018. [cited 2023 September 23]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545239/all/Dolutegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dolutegravir
ID - 545239
A1 - Smith,Janessa,Pharm.D. BCPS
AU - Pham,Paul,Pharm.D., BCPS
Y1 - 2018/09/13/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545239/all/Dolutegravir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
